Latis S.r.l.
10
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
30%
3 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy
Role: collaborator
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
Role: collaborator
ABO-GLYC in Type 2 Diabetes
Role: collaborator
Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder
Role: collaborator
Efficacy of MEMORMAX in Subjects With MCI
Role: collaborator
Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months
Role: collaborator
Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer
Role: collaborator
Study of a New Medical Device in Gel Formulation Versus Calgel® for the Topical Treatment of Teething in Infants
Role: collaborator
Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent
Role: collaborator
Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain
Role: collaborator
All 10 trials loaded